FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

hours per response:

OMB Number: 3235-0287 Estimated average burden

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ISIS]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
CROOKE STANLEY T				٦								Director			10% Ow	ner	
(Last)	(F	First)	(Middle)		Date of Earliest Transaction (Month/Day/Year)							Officer (below)	give title	ve title Other (sp below)		pecify	
C/O ISIS PHARMACEUTICALS, INC.					01/30/2013							Chair	Chairman, CEO and		President		
2855 GAZELLE COURT																	
ZOOO GAZEELEE GOOKI					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)						,			- (,,,,,	Line)			0 (
CARLSI	BAD C	A	92010)	Form fil	ed by One	Repor	ting Person		
											Form filed by More than One Reporting Person						
(City)	(5	State)	(Zip)									1 013011					
			bla I Nav D				- ^ -	and Di		f av Da		O					
			able I - Non-D			ecuritie	SAC	quirea, Di	_			Owned					
1. Title of Security (Instr. 3)						2A. Deemed Execution Date.		3. 4. Securi		ed (A) or tr. 3, 4 and 5)	5. Amoun Securities				7. Nature of ndirect		
(Month/E				onth/Day	/Year)	if any (Month/Day/Year		Code (Inst				Beneficial Owned Fo		(D) or (I) (Ins		Beneficial Ownership	
					((A) or Price		Reported Transaction(s)		(,, ((Instr. 4)		
				Code V			Amount	(A) (D)	Price	(Instr. 3 a							
			Table II - De	rivativ	e Sec	curities	Aca	uired. Dis	posed of.	or Bene	eficially (Owned					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of 2. 3. Transaction 3A. Deemed 4.					5. Number of			6. Date Exercisable and 7. Title a		7. Title an		8. Price of			10.	11. Nature	
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	Execution Date, if any		saction Derivative e (Instr. Securities			Expiration Date (Month/Day/Year)		of Securit Underlyin		Derivative Security	derivative Securities		Ownership Form:	of Indirect Beneficial	
(Instr. 3)	Price of Derivative	' '	(Month/Day/Year			Acquired (A) or Disposed		(Derivative	Derivative Security (Instr. 3 and 4)		Beneficially Owned		Direct (D) or Indirect	Ownership (Instr. 4)		
	Security				of (D) (Instr. 3, 4 and 5)					(111341.04	(our o una s)		Following Reported	g (I) (Instr. 4)			
					3, 4 and 3)		3, 4 and 3)			Amount		Transaction(s					
											or		(instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Shares						
Restricted										Common							
Stock Units	(1)	01/30/2013	01/30/2013	A		22,190		(2)	(2)	Stock	22,190	\$0	22,190		D		
				+	-								 				
Employee Stock								(2)		Common	400.466						
Option (right to	\$14.69	01/30/2013	01/30/2013	A		133,180		01/02/2014 ⁽³⁾	01/29/2020	Stock	133,180	\$0	133,18	0	D		
buy)		l	1				ıl		I	1	I	1	l	- 1			

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.
- 2. Grant of 1/30/2013 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc., 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2014. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2017. The RSU is vested as to 0 shares on January 30, 2013.
- 3. Grant of 1/30/2013 to reporting person of stock options under the Isis Pharamceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 33,295 shares per year. The option is exercisable as to 0 shares on 1/30/2013.

Remarks:

/s/Stanley T. Crooke

02/01/2013

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.